Status:
COMPLETED
[18F]-F13640 as a New Brain Radiopharmaceutical
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Neurological Pathology
Healthy Subjects
Eligibility:
MALE
20-45 years
Phase:
EARLY_PHASE1
Brief Summary
This clinical assay is designed to validate that \[18F\]F13640 as a radiotracer of 5-HT1A functional receptors. A first group of healthy subjects underwent a PET scan with arterial blood sampling to d...
Eligibility Criteria
Inclusion
- Healthy Subjects
- Weight between 50 kg and 90 kg
- Affiliated to a social security or similar scheme
- Not subject to any legal protection measures
Exclusion
- Subjects with neurologic or psychiatric disease including all substance addictions
- Daily smokers
- Active infectious disease
- MRI contraindications
- PET contraindications determined with FDG injection
- Subjects deprived of their liberty by judicial or administrative decision
- Subjects unable to sign written consent for participation in the study.
- Severe and progressive medical pathology
- Volunteer who has exceeded the annual amount of compensation authorized for participation in research protocols
Key Trial Info
Start Date :
April 23 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 2 2021
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT03347331
Start Date
April 23 2018
End Date
December 2 2021
Last Update
September 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospices Civils de Lyon
Bron, France